9 terminated. 9 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Terminated 9 |
| Phase 1 | 4 | Terminated 4 |
Follow Peripheral T-cell Lymphoma: new trials by email Literature Review of Peripheral T-cell Lymphoma trials Research Report on Peripheral T-cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma ICE [ifosfamide+carboplatin+etoposide], GEMOX [gemcitabine+oxaliplatin], Tislelizumab - Peripheral T-cell Lymphoma, NK/T-cell Lymphoma | Phase 1 / Phase 2 | Terminated | Antengene Corporation | 56 | 2020-08-18 | 2026-01-05 |
| A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma AK104 - Peripheral T-cell Lymphoma | Phase 1 / Phase 2 | Terminated | Akeso | 6 | 2020-05-15 | 2022-10-19 |
| A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors ASN002 Dose Escalation, ASN002 RD - Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell | Phase 1 / Phase 2 | Terminated | Asana BioSciences | 51 | 2015-05-01 | 2023-06-07 |
| Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas brentuximab vedotin, rituximab, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 / Phase 2 | Terminated | Northwestern University | 20 | 2013-03-05 | 2021-09-01 |
| Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant lenalidomide, rituximab, pharmacological study - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 3 | 2012-05-01 | 2017-07-27 |
| Study of Lenalidomide (Revlimid) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Patients Lenalidomide - Peripheral T-cell Lymphoma | Phase 2 | Terminated | University of Bologna | 9 | 2008-11-01 | 2012-08-27 |
| Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak) Gemcitabine, Navelbine, Doxorubicin Hydrochloride Liposome Injection - Peripheral T-Cell Lymphoma | Phase 2 | Terminated | University of California, San Francisco | 21 | 2008-07-01 | 2020-04-27 |
| The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL Alemtuzumab - Peripheral T-Cell Lymphoma | Phase 2 | Terminated | Mahidol University | 4 | 2006-09-01 | 2009-06-25 |
| A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas belinostat - Cutaneous T-Cell Lymphoma, Peripheral T-Cell Lymphoma | Phase 2 | Terminated | Valerio Therapeutics | 53 | 2006-01-01 | 2015-07-28 |
Lymphoma, T-Cell, Peripheral (9) · Lymphoma, Non-Hodgkin (4) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma, Extranodal NK-T-Cell (3) · Lymphoma, Follicular (3) · Lymphoma, Large B-Cell, Diffuse (3) · Lymphoma, Mantle-Cell (3) · Lymphoma, T-Cell, Cutaneous (3) · Burkitt Lymphoma (2) · Immunoblastic Lymphadenopathy (2) · Intraocular Lymphoma (2) · Leukemia, Hairy Cell (2) · Leukemia, Large Granular Lymphocytic (2) · Lymphoma (2) · Lymphoma, B-Cell, Marginal Zone (2)
Hemic and Lymphatic Diseases (9) · Immune System Diseases (9) · Immunoproliferative Disorders (9) · Lymphatic Diseases (9) · Lymphoma, T-Cell (9) · Lymphoproliferative Disorders (9) · Neoplasms by Histologic Type (9) · Neoplasms (8) · Lymphoma (7) · Lymphoma, Non-Hodgkin (5) · Chronic Disease (3) · Disease Attributes (3) · Hematologic Diseases (3) · Leukemia (3) · Leukemia, B-Cell (3)
Lenalidomide (2) · Rituximab (2) · Alemtuzumab (1) · Brentuximab Vedotin (1) · Carmustine (1) · Cyclophosphamide (1) · Cytarabine (1) · Doxorubicin (1) · Etoposide (1) · Gemcitabine (1) · Granulocyte Colony-Stimulating Factor (1) · Ice (1) · Leucovorin (1) · Methotrexate (1) · Vincristine (1)
Akeso (1) · Antengene Corporation (1) · Asana BioSciences (1) · Fred Hutchinson Cancer Center (1) · Mahidol University (1) · Northwestern University (1) · University of Bologna (1) · University of California, San Francisco (1) · Valerio Therapeutics (1)
United States (5) · China (2) · Thailand (2) · Argentina (1) · France (1) · Germany (1) · Israel (1) · Italy (1)
Adam Petrich, MD (1) · Jun Zhu, MD (1) · Lawrence Kaplan, MD (1) · Mohamed Sorror (1) · Niranjan Rao, PhD (1) · Surapol Issaragrisil, M.D.,Prof. (1) · Yang Yu, MD (1) · Yuqin Song, MD (1)
PMID 21504290, PMID 25404094, PMID 42438166
P30CA015704 (1)